The estimated Net Worth of Nabeel Paul Subainati is at least $99.6 Mille dollars as of 22 March 2023. Mr Subainati owns over 417 units of Avinger Inc stock worth over $99,638 and over the last 2 years he sold AVGR stock worth over $0.
Mr has made over 1 trades of the Avinger Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 417 units of AVGR stock worth $484 on 22 March 2023.
The largest trade he's ever made was exercising 417 units of Avinger Inc stock on 22 March 2023 worth over $484. On average, Mr trades about 209 units every 0 days since 2023. As of 22 March 2023 he still owns at least 85,895 units of Avinger Inc stock.
You can see the complete history of Mr Subainati stock trades at the bottom of the page.
Nabeel Subainati is the VP, Controller, Principal Financial Officer & Accounting Officer at Avinger Inc.
Mr Subainati is 38, he's been the VP, Controller e Principal Financial Officer & Accounting Officer of Avinger Inc since . There are 9 older and no younger executives at Avinger Inc. The oldest executive at Avinger Inc is James Cullen, 77, who is the Independent Chairman of the Board.
Nabeel's mailing address filed with the SEC is 400, Chesapeake Drive, Redwood City, San Mateo County, California, 94063, United States.
Over the last 10 years, insiders at Avinger Inc have traded over $4,931,811 worth of Avinger Inc stock and bought 65,650 units worth $291,405 . The most active insiders traders include John B Ph D Md Simpson, James Cullen e Jeffrey M Soinski. On average, Avinger Inc executives and independent directors trade stock every 57 days with the average trade being worth of $43,246. The most recent stock trade was executed by Nabeel Paul Subainati on 22 March 2023, trading 417 units of AVGR stock currently worth $484.
avinger, inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (pad). pad is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. the company’s mission is to radically change the way vascular disease is treated through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. avinger’s current lumivascular products include the lightbox imaging console, the ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or ctos, and pantheris, the first-ever image- guided atherectomy device, designed to precisely remove arterial plaque in pad patients.
Avinger Inc executives and other stock owners filed with the SEC include: